Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LARCID: Octreotide LAR for Prevention of Chemotherapy-Induced Diarrhea
NCT00582426Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Primary completion
- Sep 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide in diarrhea (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Developing Diarrhea (Grade 1 to 4) at 6 months. Started Apr 2008; status: completed.
02
Drugs
octreotide
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT00582426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582426.